Cantitate/Preț
Produs
Total produse
Vezi coșul
Lung Cancer: New Understandings and Therapies de Anne C. Chiang

Lung Cancer: New Understandings and Therapies: Current Cancer Research

Editat de Anne C. Chiang, Roy S. Herbst
en Limba Engleză Paperback – 2 oct 2022
Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach.  For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment.  Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 72866 lei  17-23 zile +6379 lei  10-14 zile
  Springer International Publishing – 2 oct 2022 72866 lei  17-23 zile +6379 lei  10-14 zile
Hardback (1) 109754 lei  6-8 săpt.
  Springer International Publishing – oct 2021 109754 lei  6-8 săpt.

Din seria Current Cancer Research

  • 5% Targeted Therapy of Acute Myeloid Leukemia
    Preț: 113209 lei
  • 5% Molecular Determinants of Head and Neck Cancer
    Preț: 160956 lei
  • 5% Protein Kinase C in Cancer Signaling and Therapy
    Preț: 142121 lei
  • 5% Gene-Based Therapies for Cancer
    Preț: 109408 lei
  • 5% Cell Cycle Deregulation in Cancer
    Preț: 108985 lei
  • 5% Chemical Carcinogenesis
    Preț: 148157 lei
  • 5% Molecular Determinants of Radiation Response
    Preț: 109480 lei
  • 5% Cancer Associated Viruses
    Preț: 144773 lei
  • 5% Caveolins in Cancer Pathogenesis, Prevention and Therapy
    Preț: 70697 lei
  • 5% Burkitt’s Lymphoma
    Preț: 109681 lei
  • 5% Autophagy and Cancer
    Preț: 109848 lei
  • 5% Advances in Tumor Immunology and Immunotherapy
    Preț: 111217 lei
  • 5% Targeting Autophagy in Cancer Therapy
    Preț: 71463 lei
  • 5% Asbestos and Mesothelioma
    Preț: 129722 lei
  • 5% Advances in Biology and Treatment of Glioblastoma
    Preț: 110064 lei
  • 5% Early Phase Cancer Immunotherapy
    Preț: 110395 lei
  • 5% D-type Cyclins and Cancer
    Preț: 71535 lei
  • 5% Microbiome and Cancer
    Preț: 117103 lei
  • 5% Targeted Therapies for Lung Cancer
    Preț: 90244 lei
  • 5% Engineering and Physical Approaches to Cancer
    Preț: 160847 lei
  • 5% Circulating Tumor Cells: Advances in Liquid Biopsy Technologies
    Preț: 143878 lei

Preț: 72866 lei

Preț vechi: 76700 lei
-5% Nou

Puncte Express: 1093
Preț estimativ în valută:
13944€ • 14470$ • 11655£

Carte disponibilă

Livrare economică 18-24 februarie
Livrare express 11-15 februarie pentru 7378 lei

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783030740306
ISBN-10: 3030740307
Pagini: 264
Ilustrații: VI, 264 p. 17 illus., 16 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.42 kg
Ediția:1st ed. 2021
Editura: Springer International Publishing
Colecția Humana
Seria Current Cancer Research

Locul publicării:Cham, Switzerland

Cuprins

Tumor Microenvironment: Immune Effector and Suppressor Imbalance.- Biomarkers: is tumor mutational burden the new prognostic grail?.- Liquid biopsies: new technology and evidence.- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma:  Clinical Activity and Mechanisms of Resistance.- What can we learn from acquired resistance?.- Management of Brain Metastases.- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors.- Therapeutic Advances in Small Cell Lung Cancer Management.- Small Cell Lung Cancer: Biology Advances.- Immunotherapy and Radiotherapy: New Strategies.- Ultimate Precision: Targeting Cancer but not Normal Self-Replication.- Index.

Notă biografică

Anne Chiang is an Associate Professor at Yale University’s School of Medicine and a member of the Yale Cancer Center’s Developmental Therapeutics and Thoracic Oncology Programs.  She serves as Chief Network Officer and the Deputy Chief Medical Officer at the Smilow Cancer Hospital at Yale.  Chiang earned an MD from Weill Cornell Medical College, a Ph.D. in Molecular Genetics from Harvard University and an A.B. from Princeton University in Molecular Biology.
 
Roy Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University’s School of Medicine. He serves as Chief of Medical Oncology and the Associate Director for Translational Research at the Yale Cancer Center. Herbst earned his B.S. and M.S. degrees at Yale, his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University. He has authored more than 275 publications, including peer-reviewedjournal articles, abstracts, and book chapters.

Textul de pe ultima copertă

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach.  For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment.  Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Caracteristici

Highlight recent updates in lung cancer management, both NSCLC and SCLC. Focus on translational approaches in understanding resistance biology to inform clinical management in patients treated with immuno and targeted therapies Provide the latest update on understanding and use of biomarkers in the tumor macro and microenvironment and circulating in blood Focus on changing concepts and use of immunotherapy and radiotherapy in lung cancer as well as in patients with CNS involvement